What is GLP-1 and How Does It Work?
GLP-1 Overview: GLP-1, or glucagon-like peptide-1, is a hormone naturally produced in the gut in response to eating. It regulates blood sugar and appetite by:
- Stimulating insulin release from the pancreas to lower blood glucose
- Inhibiting glucagon, which raises blood sugar
- Slowing gastric emptying to prolong feelings of fullness
- Acting on the brain to reduce hunger and cravings
Mechanism for Weight Loss: GLP-1 agonists (medications mimicking this hormone), like semaglutide, enhance these effects. This leads to reduced calorie intake and improved metabolic efficiency, resulting in significant weight reduction—often 10-20% of body weight over months. Benefits also include better blood pressure and cholesterol levels.
Key Considerations: Originally developed for type 2 diabetes, these drugs promote satiety without deprivation, making them effective for obesity. However, they work best with lifestyle changes like diet and exercise for optimal, sustained results.
Is Semaglutide the Same as Ozempic?
Core Relationship: Semaglutide is the active ingredient, a GLP-1 receptor agonist that mimics the GLP-1 hormone to regulate blood sugar and appetite, aiding weight loss. Ozempic is a brand-name version of semaglutide.
Key Differences and Similarities
- Ozempic: FDA-approved mainly for type 2 diabetes; lowers blood glucose and reduces cardiovascular risks. Administered as a weekly injection, starting at lower doses.
- Wegovy: Another semaglutide brand, approved for chronic weight management in obesity or overweight with comorbidities. Uses higher doses optimized for weight loss.
- Both contain the same semaglutide molecule but differ in dosing and primary indications.
Other Forms: Compounded semaglutide (custom-made) is not FDA-approved and may vary in quality, unlike branded versions.
Bottom Line: Ozempic is semaglutide, but semaglutide comes in multiple branded forms tailored to specific uses.
Side Effects
Common Gastrointestinal Issues
Affecting up to 50% of users, especially early on or during dose increases:
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
- Bloating
- Heartburn
These often resolve as the body adjusts.
Other Frequent Effects
- Loss of appetite
- Fatigue
- Dizziness
- Headaches
- Injection site reactions (e.g., redness, swelling)
Rapid weight loss can cause “Ozempic face”—sagging skin from facial fat loss.
Serious but Less Common Risks
- Pancreatitis (severe abdominal pain)
- Gallbladder disorders (e.g., gallstones)
- Kidney injury
- Rare thyroid tumors (seen in rodents; human risk unclear)
Additional Concerns: Compounded versions may increase risks due to dosing errors or impurities, sometimes leading to hospitalization. Muscle loss (sarcopenia) from rapid weight reduction is possible.
Advice: Monitor symptoms closely and discontinue if severe. Consult a doctor for management.
GLP-1 Injection vs Oral – Pros and Cons
Overview: GLP-1 agonists are available as injections (e.g., semaglutide in Ozempic/Wegovy) or oral tablets (e.g., Rybelsus). Choice depends on preferences, tolerability, and efficacy needs.
Injections (Weekly)
- Pros: Consistent absorption; greater weight loss (up to 15-20% body weight); reliable blood levels; fewer daily doses; stronger appetite control and metabolic benefits.
- Cons: Require needles (causing discomfort or anxiety); potential injection site reactions; higher cost; not suitable for needle-phobic individuals.
Oral Forms (Daily Tablets)
- Pros: Needle-free for better adherence; similar glycemic control; convenient pill format.
- Cons: Lower absorption due to stomach acid/enzymes; less weight loss (typically 5-10%); more gastrointestinal side effects; must be taken on empty stomach with water; daily dosing raises discontinuation risk.
Comparison Insights: Studies show injections yield 1-2 kg more weight reduction. Orals suit pill-preferring users, while injections are ideal for maximum efficacy.
How Long Can They Take to Work?
Initial Effects: GLP-1 agonists like semaglutide start suppressing appetite within days, often noticeable in 1-4 weeks via slowed gastric emptying and stronger fullness signals. Early weight loss is minor (2-4% body weight) by week 4.
Dose Titration and Progression: Starts low to minimize side effects, with increases every 4 weeks. Significant reduction (5-10%) appears around 8-12 weeks.
Full Impact Timeline: Plateaus at 6-12 months with up to 15-20% total loss. In trials, changes begin at week 4, peaking at week 60.
Influencing Factors
- Dosage and adherence
- Diet and exercise
- Individual metabolism
Blood sugar improvements may occur faster than visible weight loss.
Key Advice: Be patient and combine with lifestyle changes. Discontinuation often leads to regain within months.
How to Choose the Right Weight Loss Medication?
Eligibility Check: Ideal for BMI ≥30 or ≥27 with comorbidities (e.g., hypertension, diabetes). Assess health history and goals with a doctor.
Evaluation Factors
- Risks and Contraindications: Screen for gastrointestinal tolerance or issues like thyroid cancer history.
- Efficacy Comparison: Tirzepatide (Zepbound/Mounjaro) often yields more loss (up to 22%) than semaglutide (15-16%), but semaglutide is well-established.
- Administration: Weekly injections (convenient but needle-based) vs. daily orals (needle-free but with stricter intake rules).
- Other Considerations: Cost ($800-1200/month; insurance-dependent), side effects, muscle preservation (pair with exercise/diet to reduce sarcopenia).
Practical Steps: Prioritize FDA-approved options over compounded. Monitor for 12 weeks; switch if ineffective. Expect long-term use, as stopping causes regain.
Ready to Start Your Weight Loss Journey?
Sources
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. [PMID: 33567185]
- Neeland IJ, et al. Changes in lean body mass with glucagon-like peptide-1-based therapies. Diabetes Obes Metab. 2024;26(9):3763-3775. [PMID: 38937282]
- Pantazopoulos D, et al. GLP-1 receptor agonists and sarcopenia. Endocrine. 2024. [PMID: 41022269]
- Dai Y, et al. Efficacy and Safety of GLP-1 Receptor Agonists on Body Weight. Endocr Pract. 2024;30(2):160-173. [PMID: 38029929]
- Chavda VP, et al. Weight Gain following Discontinuation of GLP-1 Receptor Agonists. J Diabetes Res. 2024. [PMID: 38765635]
- Bhandarkar A, et al. Effect of GLP-1 receptor agonists on body composition. Curr Opin Endocrinol Diabetes Obes. 2025;32(1):1-6. [PMID: 41076575]
- Puri S, et al. Efficacy and Safety of GLP-1 Receptor Agonists for Weight Loss. Ann Intern Med. 2024;177(10):1365-1379. [PMID: 39761578]
- Bhandari M, et al. Weight loss between GLP-1 receptor agonists and bariatric surgery. Obesity. 2022;30(12):2331-2341. [PMID: 36321278]
- Alkhezi OS, et al. Comparative effectiveness of GLP-1 receptor agonists. Curr Med Res Opin. 2022;38(2):261-273. [PMID: 34751094]